";s:4:"text";s:5091:" The AUCRegarding drug interaction in the absorption of ilaprazole, a previous study by Cao et al. You can also search for this author in Food and Drug Administration. 2016 Sep;33(9):1519-35. doi: 10.1007/s12325-016-0374-x. Epub 2012 Jul 23.Sakurai Y, Shiino M, Okamoto H, Nishimura A, Nakamura K, Hasegawa S.Adv Ther. Considering that the power of the parallel study design would be insufficient compared with that of the crossover design, the minimum number of subjects was estimated to be 28, consisting of 14 subjects/per part, and the total number of subjects was 32 (16 subjects/part) under the assumption of a potential drop-out rate of 15%. The assessments included monitoring of all adverse events (AEs) based on physical examinations, vital signs, 12-lead ECG, routine haematology, serum chemistry, and urinalysis.
For ilaprazole, the peak concentration (CThe coadministration of ilaprazole, clarithromycin, and amoxicillin was tolerable and did not cause a significant PK drug interaction. Pharmacol Res 49:493–499Mainz D, Borner K, Koeppe P, Kotwas J, Lode H (2002) Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. The aim of this study was to evaluate pharmacokinetic drug interactions and safety profiles after coadministration of clarithromycin, amoxicillin, and ilaprazole. Notes: Subjects who were assigned to part 1 received ilaprazole 10 mg on day 1 of period 1 and clarithromycin 500 mg and amoxicillin 1000 mg from day 1 to day 6 of period 2 and ilaprazole 10 mg was concomitantly administered on day 5 of period 2. Pharmacokinetic drug interaction and safety after coadministration of clarithromycin, amoxicillin, and ilaprazole: a randomised, open-label, one-way crossover, two parallel sequences study Gastroenterology 111:358–367de Bortoli N, Martinucci I, Giacchino M, Blandizzi C, Marchi S, Savarino V, Savarino E (2013) The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment. 2008 Aug;13(4):282-7. doi: 10.1111/j.1523-5378.2008.00615.x.Mansour NM, Hashash JG, El-Halabi M, Ghaith O, Maasri K, Sukkarieh I, Malli A, Sharara AI.Eur J Gastroenterol Hepatol. One subject was dropped during period 1 because of smoking in part 2. COVID-19 is an emerging, rapidly evolving situation.Jung Hye Kim, Jun Yeon Lee, and Jae Soo Shin are employees of IL-YANG Pharmaceutical Co., Ltd. Drug interactions with clarithromycin include: Antidiabetic drugs and insulin — the concurrent use of clarithromycin and antidiabetic drugs (such as sulphonylurias and/or insulin) can result in … Mean (SD) plasma concentration-time profiles of amoxicillin when administered as dual therapy and as part of triple therapy. Mean (SD) plasma concentration-time profiles of clarithromycin when administered as dual therapy and as part of triple therapy. Clin Chim Acta 391:60–67Myung SW, Min HK, Jin C, Kim M, Lee SM, Chung GJ, Park SJ, Kim DY, Cho HW (1999) Identification of IY81149 and its metabolites in the rat plasma using the on-line HPLC/ESI mass spectrometry. Subjects who were assigned to part 2 received both clarithromycin 500 mg and amoxicillin 1000 mg on day 1 of period 1 and ilaprazole 10 mg from day 1 to day 6 of period 2 and clarithromycin 500 mg and amoxicillin 1000 mg was concomitantly administered on day 5 of period 2The study was approved by the Institutional Review Board of Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, and conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice.Serial blood samples were collected in anti-coagulated EDTA-K2 tubes at 0 (pre-dose), 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, and 48 h after dosing of ilaprazole in part 1. METHODS: A randomised, open-label, one-way crossover, two parallel sequences study was conducted in 32 healthy subjects. Clin Pharmacol Ther 68:304–311Vallve M, Vergara M, Gisbert JP, Calvet X (2002) Single vs. double dose of a proton pump inhibitor in triple therapy for Li Y, Zhang W, Guo D, Zhou G, Zhou H, Xiao Z (2008) Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes.